GVHD
Clinical trials for GVHD explained in plain language.
Never miss a new study
Get alerted when new GVHD trials appear
Sign up with your email to follow new studies for GVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New approach aims to tame dangerous transplant side effect
Disease control CompletedThis study tested whether a new combination of two drugs (cyclophosphamide and abatacept) could better prevent a serious complication called graft-versus-host disease (GVHD) after stem cell transplants for blood cancers. GVHD happens when donor immune cells attack the patient's b…
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: Dimitrios Tzachanis, MD PhD • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug aims to stop dangerous transplant complication
Prevention CompletedThis study tested if adding a new drug called BMS-986004 to standard anti-rejection medicine could safely prevent a serious complication called acute Graft-Versus-Host Disease (GVHD). It involved 45 patients with blood cancers who received a stem cell transplant from a donor. The…
Matched conditions: GVHD
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated Mar 31, 2026 12:12 UTC
-
New hope to stop dangerous transplant complication
Prevention CompletedThis study tested if adding a drug called pacritinib to standard anti-rejection medicines could better prevent graft-versus-host disease (GVHD) after a stem cell transplant. It involved 40 patients with blood cancers who received matched donor transplants. Researchers measured in…
Matched conditions: GVHD
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test 'Smart' immune protein in lab to calm autoimmune attacks
Knowledge-focused CompletedThis was a small, completed lab study that tested whether specially engineered versions of a natural immune protein (called IL-2 muteins) could selectively boost a type of calming immune cell (regulatory T cells) taken from patients with various autoimmune and inflammatory diseas…
Matched conditions: GVHD
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC